Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Stephen J Greene Added: 4 days ago
ESC HF 25 - VELOCITY shows bypassing an initiation dose of 2.5mg, and and beginning with 5mg vericiguat safe and tolerable in 9/10 patients with heart failure with ejection fraction <45%.Prof Stephen Greene (Duke Clinical Research Institute, US) discusses the findings from VELOCITY (NCT06195930; Bayer), a phase 2b open-label clinical study evaluating the tolerability and safety of an… View more
Author(s): Ruth Masterson Creber Added: 1 month ago
ACC 25 - Findings of the MIGHTy-Heart study shows no difference between mobile integrated healthcare and a traditional transitions of care coordinator approach in 30-day all-cause readmissions or health status.Dr Ruth Masterson Creber (Columbia University, New York, US) joins us onsite at ACC to discuss the findings from MIGHTy-Heart, a comparative effectiveness study that evaluated two different… View more